CA1214725A - Comprimes vaginaux contraceptifs et methode de preparation - Google Patents

Comprimes vaginaux contraceptifs et methode de preparation

Info

Publication number: CA1214725A
Authority: CA; Canada
Prior art keywords: weight; parts; tablets; vitamin; sodium bisulfite
Prior art date: 1983-11-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000441915A

Other languages

English (en)

Inventor

Bela Koszegi

Andras Kovacs

Rudolf Szebeni

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-11-24

Filing date

1983-11-24

Publication date

1986-12-02

1983-11-24 Application filed by Individual filed Critical Individual

1983-11-24 Priority to CA000441915A priority Critical patent/CA1214725A/fr

1986-12-02 Application granted granted Critical

1986-12-02 Publication of CA1214725A publication Critical patent/CA1214725A/fr

Status Expired legal-status Critical Current

Links

230000002254 contraceptive effect Effects 0.000 title claims abstract description 17
239000000003 vaginal tablet Substances 0.000 title claims abstract description 17
239000003433 contraceptive agent Substances 0.000 title claims abstract description 16
238000004519 manufacturing process Methods 0.000 title claims abstract description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 44
239000003826 tablet Substances 0.000 claims abstract description 31
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 25
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 25
239000004327 boric acid Substances 0.000 claims abstract description 25
235000002906 tartaric acid Nutrition 0.000 claims abstract description 25
239000011975 tartaric acid Substances 0.000 claims abstract description 25
229960004051 menadione sodium bisulfite Drugs 0.000 claims abstract description 24
XDPFHGWVCTXHDX-UHFFFAOYSA-M menadione sodium sulfonate Chemical compound [Na+].C1=CC=C2C(=O)C(C)(S([O-])(=O)=O)CC(=O)C2=C1 XDPFHGWVCTXHDX-UHFFFAOYSA-M 0.000 claims abstract description 24
235000019359 magnesium stearate Nutrition 0.000 claims abstract description 22
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 21
239000008101 lactose Substances 0.000 claims abstract description 21
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 21
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 21
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 21
239000000203 mixture Substances 0.000 claims abstract description 20
229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 19
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 19
235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 19
239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 19
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
229940044977 vaginal tablet Drugs 0.000 claims description 8
239000000843 powder Substances 0.000 abstract description 5
238000002360 preparation method Methods 0.000 description 14
238000000034 method Methods 0.000 description 11
230000003054 hormonal effect Effects 0.000 description 5
239000005556 hormone Substances 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000001215 vagina Anatomy 0.000 description 4
238000001727 in vivo Methods 0.000 description 3
230000035935 pregnancy Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000015943 Coeliac disease Diseases 0.000 description 2
206010023126 Jaundice Diseases 0.000 description 2
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002262 irrigation Effects 0.000 description 2
238000003973 irrigation Methods 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
208000008599 Biliary fistula Diseases 0.000 description 1
206010048611 Cholaemia Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000000616 Hemoptysis Diseases 0.000 description 1
241001662043 Icterus Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
206010041969 Steatorrhoea Diseases 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
231100000812 repeated exposure Toxicity 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
206010040400 serum sickness Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
230000001150 spermicidal effect Effects 0.000 description 1
208000001162 steatorrhea Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000012711 vitamin K3 Nutrition 0.000 description 1
239000011652 vitamin K3 Substances 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

CA000441915A 1983-11-24 1983-11-24 Comprimes vaginaux contraceptifs et methode de preparation Expired CA1214725A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000441915A CA1214725A (fr)	1983-11-24	1983-11-24	Comprimes vaginaux contraceptifs et methode de preparation

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000441915A CA1214725A (fr)	1983-11-24	1983-11-24	Comprimes vaginaux contraceptifs et methode de preparation

Publications (1)

Publication Number	Publication Date
CA1214725A true CA1214725A (fr)	1986-12-02

Family

ID=4126595

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000441915A Expired CA1214725A (fr)	1983-11-24	1983-11-24	Comprimes vaginaux contraceptifs et methode de preparation

Country Status (1)

Country	Link
CA (1)	CA1214725A (fr)

1983
- 1983-11-24 CA CA000441915A patent/CA1214725A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2003-12-02	MKEX	Expiry

Publication	Publication Date	Title
El-Beheiry et al.	1979	Methotrexate and fertility in men
Chvapil et al.	1980	Studies on nonoxynol-9. II. Intravaginal absorption, distribution, metabolism and excretion in rats and rabbits
Scheinhorn et al.	1977	Antituberculous therapy in pregnancy: risks to the fetus
NOYES	1959	The underdeveloped secretory endometrium
US4565694A (en)	1986-01-21	Contraceptive vaginal tablets
Eckstein et al.	1972	Clinical and laboratory findings in a trial of norgestrel, a low-dose progestogen-only contraceptive
EP0472791A1 (fr)	1992-03-04	Compositions contenant de l'huile de margousier pour la régulation de la fertilité et la prévention de la grossesse
Tietze	1965	History of contraceptive methods
Croxatto et al.	1975	Clinical assessment of subdermal implants of megestrol acetate, d-norgestrel, and norethindrone as a longterm contraceptive in women
Abrutyn et al.	1982	Teratology study of intravaginally administered nonoxynol-9-containing contraceptive cream in rats
Cicero et al.	1994	Acute alcohol exposure markedly influences male fertility and fetal outcome in the male rat
NZ206039A (en)	1985-09-13	Contraceptive vaginal tablets containing boric acid and vitamin k3
Wilk	1969	Production of fetal rat malformations by norchlorcyclizine and chlorcyclizine after intrauterine application
Prema et al.	1980	Serum copper in long-term users of copper intrauterine devices
Dipaolo et al.	1964	Malformations induced in the mouse by thalidomide
Normington et al.	1972	Hypertension and oedema complicating pregnancy in Addison's disease
Barlow et al.	1983	Teratogenic effects of Silastic intrauterine devices in the rat with or without added medroxyprogesterone acetate
GB2121289A (en)	1983-12-21	Intrauterine contraceptive device and method of its production
Juneja et al.	1993	Mouse sperm-egg interaction in vitro in the presence of neem oil
Biskind et al.	1943	Inactivation of estrone in normal male rabbits
Armstrong et al.	1959	Metallic intrauterine foreign body in term pregnancy: Case report
Leone	1974	" Uterine progesterone system (UPS)": a new form of intrauterine contraception. Preliminary report
Loewit et al.	1971	Contraceptive effect of iron. Reduced fertility after vaginal application of iron chloride in rats
Quigg et al.	1988	Development of the polyurethane sponge as a delivery system for aryl 4-guanidinobenzoates
NO163842B (no)	1990-04-23	Svangerskapshindrende vaginale tabletter.